Get a new indication!

On January 6, 2022, Pfizer announced that the State Drug Administration approved the innovative drug Kangxinbo (isavuconazole sulfate capsules, CRESEMBA, 100mg) for the treatment of invasive aspergillosis in adults
.

This is the second indication approved in China after Kangxinbo's invasive mucormycosis indication was approved

On January 6, 2022, Pfizer announced that the State Drug Administration approved the innovative drug Kangxinbo (isavuconazole sulfate capsules, CRESEMBA, 100mg) for the treatment of invasive aspergillosis in adults

Invasive aspergillosis can affect the lungs, central nervous system or bones, eyes, sinuses and other parts of the body

Invasive aspergillosis and invasive mucormycosis are both invasive mycosis and are often indistinguishable in early diagnosis

At present, China is facing many challenges in the field of clinical treatment of invasive mycosis, mainly reflected in treatment tolerance, drug interactions, long-term treatment compliance, and the need to monitor drug concentrations
.

As a new broad-spectrum triazole antifungal drug, Kangxinbo has successively been approved for two indications of invasive mucormycosis and invasive aspergillosis in adults, which will help the whole treatment of clinical invasive mycosis
.
In the 2017 ECIL-6 "Guidelines for Invasive Candidiasis, Aspergillosis and Mucormycosis in Patients with Leukemia and Hematopoietic Stem Cell Transplantation", isavuconazole is recommended as first-line treatment for invasive aspergillosis, and in 2017 ESCMID-ECMM-ERS " In the Guidelines for the Diagnosis and Management of Aspergillosis, isavuconazole is recommended as first-line treatment for invasive pulmonary aspergillosis
.

Zhenke Peng, President of Pfizer Biopharmaceutical Group China, said, "Pfizer aims to 'bring breakthrough innovations that change patients' lives'.
Adult patients with invasive aspergillosis and invasive mucormycosis provide innovative treatment options to help clinicians actively respond to the threat of this type of disease
.
We will speed up the marketing process and make this innovative drug available to Chinese patients as soon as possible
.
"
Currently, Kangxinbo is in the United States , the United Kingdom, France, Switzerland and more than 60 countries and regions have been approved
.
leave a message here